Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica.
Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand.
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.
Differential roles of microglia and monocytes in the inflamed central nervous system.
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Sanofi MS drug nears green light after pass-the-parcel marathon
A genome-wide association study of brain lesion distribution in multiple sclerosis.
Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.
Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
Genmab Announces Ofatumumab Development Plans in RRMS and NMO
Ofatumumab
Volumetric comparisons of supratentorial white matter hyperintensities on FLAIR MRI in patients with migraine and multiple sclerosis.
Amiloride: a molecular probe of sodium transport in tissues and cells.
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b)
Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?
BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
Laquinimod Phase IIa Study in Active Crohn's Disease
Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.

Pages